Evolus, Inc.
EOLS
$0.02
Change (1 day)
$17.82
Year High
$9.80
Year Low
Categories
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Revenue of Evolus, Inc. (EOLS)
Revenue in 2023 (TTM): $202.09 M
According to Evolus, Inc.'s latest financial reports the company's current revenue (TTM) is $202.09 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Evolus, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $202.09 M | $140.53 M | $-41,810,000 | $-61,509,000 | $-61,685,000 |
| 2022 | $148.62 M | $92.73 M | $-60,723,000 | $-74,317,000 | $-74,412,000 |
| 2021 | $99.67 M | $56.14 M | $-39,058,000 | $-46,768,000 | $-46,810,000 |
| 2020 | $56.54 M | $38.24 M | $-144,752,000 | $-162,936,000 | $-163,013,000 |
| 2019 | $34.93 M | $26.91 M | $-92,103,000 | $-105,061,000 | $-90,034,000 |
| 2018 | $ | $-9,000 | $-46,133,000 | $-46,802,000 | $-46,867,000 |
| 2017 | $ | $-218,000 | $-11,508,000 | $-11,731,000 | $-4,480,000 |
| 2016 | $ | $-326,000 | $-19,640,000 | $-19,972,000 | $-20,065,000 |
| 2015 | $ | $-416,000 | $-30,564,000 | $-31,019,000 | $-31,112,000 |